Raymond James Financial
AARD

Raymond James Financial’s Aardvark Therapeutics AARD Stock Holding History

Raymond James Financial’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.1K Buy
+10,890
New +$113K ﹤0.01% 5142

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Raymond James Financial's AARD Position: Q1 2026 in Review

Raymond James Financial opened a new position in Aardvark Therapeutics (AARD) in Q1 2026: 10,890 shares worth $41.1K. The stake represents ﹤0.01% of the portfolio and ranks #5142 among its holdings.

79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Raymond James Financial held 10,890 shares of Aardvark Therapeutics worth $41.1K as of Q1 2026.
  • Aardvark Therapeutics was a new Raymond James Financial position in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5142 holding.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.